CSL posts strong profit but investors unimpressed
Investors didn’t like the annual results and outlook from Australia’s home-grown “Big Pharma”, CSL (ASX:CSL).
Read MoreTag: CSL
Deep dive into CSL, NUF & IPH and charts on China risks
Fund Manager Chris Pedersen looks at CSL (ASX:CSL), Nufarm (ASX:NUF), IPH (ASX:IPH) and charts on China risks.
Read MoreHeated audience at CSL’s AGM
CSL's (ASX:CSL) Annual General Meeting in Melbourne on Wednesday turned into a heated discussion regarding executive pay and a declining share price, casting a shadow over the reaffirmation of guidance for the upcoming year.
Read MoreShareholders to receive more from CSL as revenue and earnings surge
Shareholders of the blood products giant CSL (ASX:ASX) are set to benefit as the company increased its revenue and earnings in the year leading up to June 30.
Read MoreMarket Smells Blood, Gives CSL a Whack
Shares in pharma giant CSL took a hit yesterday after it revealed a larger than forecast loss from currency movements for its FY2022-23.
Read MoreAirlie FM April 2023 Quarterly Update
Airlie FM’s Emma Fisher provides her views on the current market environment and discusses her recent trip to Europe where she visited the HQs of key holdings CSL and QBE Insurance.
Read MoreIndustrials Intel: JHX, CSL, ANN
A bit of a mixed bag from three of our big industrial companies on Tuesday, with James Hardie and Ansell both taking a recent earnings hit but old reliable CSL still going strong.
Read MoreBourse Discourse: CSL, EDV
One could almost be excused for thinking we are in the middle of a roaring bull market in the context of very upbeat presentations on Monday from CSL and Endeavour Group.
Read MoreStock Snippets: CRN, CSL
Word of possible takeover talks with Peabody Energy sent shares in coal miner Coronado charging Wednesday, while CSL also brought some good news to the market.
Read MoreFlu Division Helps Immunise CSL’s Bottom Line
Lower blood plasma collection volumes meant CSL had a 6% fall in full-year profit, but a bumper year for the Seqirus flu vaccine business pushed revenues higher for the year to June.
Read MoreCSL – Macquarie rates the stock as Outperform
The Outperform rating and target price of $312.00 are retained.
Read MoreCSL – Macquarie rates the stock as Outperform
The broker retains an Outperform rating and lowers the target to $312.00 from $327.25.
Read MoreCSL – Morgans rates the stock as Add
Add rating retained. Target price eases to $327.60 from $334.70.
Read MoreCSL Shares Rally Strongly Despite Earnings Dip
As many analysts had forecast, constraints on plasma collection (especially in the US) led to a small dip in December half-year earnings for blood products colossus CSL.
Read MoreCSL – Morgans rates the stock as Add
Add rating is maintained. Target price rises to $334.7 from $324.4.
Read MoreCSL Finally Confirms $A16 Billion Vifor Deal
CSL announced late Tuesday that it has struck a deal to buy Swiss-based Vifor Pharma Ltd for $A16.4 billion, its biggest deal since listing in 1994.
Read MoreCSL Confirms Vifor Talks
After weeks of speculation that CSL was looking to bid for Swiss pharma firm Vifor, the companies have today confirmed they are in talks.
Read MoreCSL – Credit Suisse rates the stock as Neutral
The $315 target and Neutral rating are unchanged.
Read MoreCSL – Morgans rates the stock as Add
Morgans increases its CSL target price to $324.40 from $301.1. The Add rating is unchanged.
Read MoreProfit Briefs: CSL, AMC
With peak reporting season upon us, here are snippets from the results announced yesterday by a couple of big-name multinational companies: CSL Limited and Amcor.
Read MoreCSL – Citi rates the stock as Downgrade to Neutral
Citi downgrades to Neutral from Buy given the stock has outperformed since March. Target is steady at $310.
Read MoreCSL – Macquarie rates the stock as Outperform
After various adjustments, overall EPS forecast revisions result in the target moving to $312 from $296. The Outperform rating is maintained.
Read MoreCSL – Macquarie rates the stock as Neutral
After reviewing the drivers of 14% per annum gross profit growth during FY2016-20, Macquarie assumes a recovery for Ig. The Neutral rating is maintained while the price target falls to $288 from $293.
Read MoreCSL – Morgans rates the stock as Upgrade to Add
With underperformance in the shares, no structural concerns and technicals being supportive, Morgans believes the risk/reward is more attractive for CSL and upgrades the rating to Add from Hold. No changes to forecasts or the price target of $301.1.
Read MoreCSL – UBS rates the stock as Buy
Despite a robust first half result , UBS expects a significantly lower second half net profit. Buy rating retained. Target is reduced to $330 from $339.
Read MoreCOVID a Tonic For CSL, Sonic
COVID has been good news for two of Australia’s health giants – Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read MoreCSL – Citi rates the stock as Neutral
Global immunology company Argenx has announced the expansion of a trial, the outcome of which is potentially negative for CSL, warns Citi. The Neutral rating and $320 target are unchanged.
Read MoreASX Poised For Weak Open As CSL Dumps Vaccine Trial
The ASX will be hit not only by uncertain trading on Wall Street overnight but by the news that CSL and Queensland University had abandoned their attempts to create a COVID-19 vaccine.
Read MoreCSL – Macquarie rates the stock as Neutral
Macquarie notes foot traffic for around 100 of the US-based collection centres has eased after hitting a new peak mid November. In conjunction, coronavirus cases in the US have increased.
Read MoreCanberra Provides CSL With New Vaccine Boost
Melbourne will see a new high-tech vaccine manufacturing plant in a billion-dollar deal to secure the nation’s long-term supply of critical health products including influenza vaccines and life-saving anti-venoms.
Read MoreCSL – Macquarie rates the stock as Neutral
Foot traffic at around 100 of the company’s US-based collection centres has eased in recent weeks. New coronavirus cases in the US have increased and the current seven-day rolling average is ahead of the previous peak.
Read MoreCSL – UBS rates the stock as Buy
UBS observes 139m flu vaccine doses have been distributed for the US flu season till October 9, up 9% versus last year. CSL also reported having increased its supply of flu vaccine into the US to circa 60m doses for the 20-21 season, a 20% increase from last year.
Read MoreCSL – UBS rates the stock as Buy
While CSL is still some way with respect to plasma collection volumes seen last year, UBS believes there are a range of mitigation measures and positive drivers to underpin growth in FY21.
Read MoreCSL Tightens Guidance As Investors Zone In On Vaccine Boost
Blood plasma giant CSL has raised the lower end of its profit guidance for the 2021 June 30, predicting growth of between 3% and 8% in the range of $2.17 to $2.65 billion – a tightening from its August results where the lower end of growth was for no growth.
Read MoreCSL Seals UQ Covid Vaccine Production Deal
CSL shares rose yesterday after its coronavirus vaccine plans formed up. CSL confirmed the sealing of a deal with the federal government to produce the University of Queensland’s COVID-19 vaccine.
Read MoreCSL – Macquarie rates the stock as Neutral
Macquarie notes foot traffic for around 100 of the US-based collection centres has eased in recent weeks and an increase in new coronavirus cases has been noted over the same period. Current foot traffic sits around -17% below average.
Read MoreCSL – Credit Suisse rates the stock as Outperform
Credit Suisse believes the pandemic will promote a sustained increase in flu vaccination rates over the next 2-3 years.
Read MoreSpotlight On CSL Revenue Targets
CSL is highly likely to be looking for other avenues of revenue to meet targets in FY21, given a prospective shortfall in plasma collections.
Read MoreCSL Delivers Again With Higher Profit, Increased Dividend
Thumbs up from investors for CSL’s latest full-year results and confident outlook for the 2020-21 financial year. Australia’s global pharma giant said yesterday it is looking for an 8% rise in earnings for 2020-21 after reporting record sales and a record dividend for 2019-20, despite all the uncertainties caused by the COVID-19 pandemic.
Read MoreCSL – UBS rates the stock as Buy
UBS reviews implications for plasma collection with the rise in coronavirus cases in certain US states. The broker expects a decline of -20% on average from April-September 2020 and then no growth until March 2021.
Read More
